Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer

Cell Cycle

Volumn 11, Issue 7, 2012, Pages 1468-1476

  Akli, Said ^a   Zhang, Xin Qiao ^a   Bondaruk, Jolanta ^a   Tucker, Susan L ^a   Czerniak, P Bogdan ^a   Benedict, William F ^a   Keyomarsi, Khandan ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Bladder cancer; Cdk2 kinase; Cell cycle; Cyclin E; p27

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLIN E KINASE; PHOSPHOTRANSFERASE; PROTEIN P21; PROTEIN P27; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

EID: 84860347330     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.19882     Document Type: Article

References (32)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al.; American Cancer Society. Cancer statistics. CA Cancer J Clin 2004; 54:8-29; PMID:14974761; http://dx.doi.org/10.3322/canjclin.54.1.8.
2. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, et al. Focus on bladder cancer. Cancer Cell 2004; 6:111-6; PMID:15324694; http://dx.doi.org/10.1016/j.ccr.2004.08.002.
3. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2003; 2:38-47; PMID:14508079.
4. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005; 24:2776-86; PMID:15838514; http://dx.doi.org/10.1038/sj.onc. 1208613.
5. Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, Tanaka T, et al. Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res 2004; 64:4800-9; PMID:15256449; http://dx.doi.org/10.1158/0008-5472.CAN-03-3908.
6. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003; 200:375-82; PMID:12845634; http://dx.doi.org/10.1002/path.1356.
7. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13:41-7; PMID:12507555; http://dx.doi.org/10.1016/S1044-579X(02)00098-6.
8. bw7 ubiquitin ligase. Science 2001; 294:173-7; PMID:11533444; http://dx.doi.org/10. 1126/science.1065203.
9. Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, et al. hCDC4 gene mutations in endometrial cancer. Cancer Res 2002; 62:4535-9; PMID:12183400.
10. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004; 428:77-81; PMID:14999283; http://dx.doi.org/10.1038/nature02313.
11. Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Moqadam FA, et al. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle 2011; 10:2172-83; PMID:21597324; http://dx.doi.org/10. 4161/cc.10.13.16248.
12. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27 and antiestrogens in breast cancer. Cancer Res 2004; 64:3198-208; PMID:15126360; http://dx.doi.org/10.1158/0008-5472.CAN-03-3672.
13. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001; 21:6254-69; PMID:11509668; http://dx.doi.org/10.1128/MCB.21.18.6254-69.2001.
14. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 2010; 70:5074-84; PMID:20530685; http://dx.doi.org/10.1158/0008-5472.CAN-09-4094.
15. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-75; PMID:12432043; http://dx.doi.org/10.1056/NEJMoa021153.
16. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 2004; 23:2648-57; PMID:15007381; http://dx.doi.org/10.1038/sj.onc.1207408.
17. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, et al. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 2005; 65:692-7; PMID:15705861.
18. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000; 157:787-94; PMID:10980118; http://dx.doi.org/10.1016/S0002-9440(10)64592-0.
19. McGarvey TW, Tait E, Tomaszewski JE, Malkowicz SB. Expression of Transforming Growth Factorbeta Receptors and Related Cell-Cycle Components in Transitional-Cell Carcinoma of the Bladder. Mol Urol 1999; 3:371-80; PMID:10851298.
20. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999; 155:1129-36; PMID:10514396; http://dx.doi.org/10.1016/S0002-9440(10)65216-9.
21. Shibayama T, Tachibana M, Deguchi N, Jitsukawa S, Tazaki H. SCID mice: a suitable model for experimental studies of urologic malignancies. J Urol 1991; 146:1136-7; PMID:1895440.
22. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995; 154:1532-8; PMID:7658585; http://dx.doi.org/10.1016/S0022-5347(01)66923-4.
23. Vidal A, Koff A. Cell cycle inhibitors: three families united by a common cause. Gene 2000; 247:1-15; PMID:10773440; http://dx.doi.org/10.1016/S0378- 1119(00)00092-5.
24. Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 2001; 61:6583-91; PMID:11522658.
25. Kip1 mislocalization. Oncogene 2000; 19:5926-35; PMID:11127824; http://dx.doi.org/10. 1038/sj.onc.1203991.
26. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/Akt mediates cell cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8:1145-52; PMID:12244301; http://dx.doi.org/10.1038/nm759.
27. Bhatia B, Malik A, Fernandez-L A, Kenney AM. p27(Kip1), a double-edged sword in Shh-mediated medulloblastoma: Tumor accelerator and suppressor. Cell Cycle 2010; 9:4307-14; PMID:21051932; http://dx.doi.org/10.4161/cc.9.21.13441.
28. Kip1. Hum Pathol 2000; 31:751-60; PMID:10872671; http://dx.doi.org/10.1053/hupa.2000.8227.
29. Lacoste-Collin L, Gomez-Brouchet A, Escourrou G, Delisle MB, Levade T, Uro-Coste E. Expression of p27(Kip1) in bladder cancers: immunohistochemical study and prognostic value in a series of 95 cases. Cancer Lett 2002; 186:115-20; PMID:12183083; http://dx.doi.org/10.1016/S0304-3835(02)00319-1.
30. Franke KH, Miklosi M, Goebell P, Clasen S, Steinhoff C, Anastasiadis AG, et al. Cyclin-dependent kinase inhibitor p27(KIP1) is expressed preferentially in early stages of urothelial carcinoma. Urology 2000; 56:689-95; PMID:11018640; http://dx.doi.org/10.1016/S0090-4295(00)00678-6.
31. Santos LL, Amaro T, Pereira SA, Lameiras CR, Lopes P, Bento MJ, et al. Expression of cell cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 2003; 29:74-80; PMID:12559081; http://dx.doi.org/10.1053/ejso.2002.1371.
32. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54:380-5; PMID:7903908.